Roux-en-Y gastric bypass surgery improves hepatic glucose metabolism and reduces plasma Kisspeptin levels in morbidly obese patients with type 2 diabetes.
Roux-en-Y gastric bypass surgery (RYGB) is known to improve whole-body glucose metabolism in patients with type 2 diabetes (T2D), although the mechanism(s) are not entirely clear and likely multi-factorial. The aim of this study was to assess fasting hepatic glucose metabolism and other markers of metabolic activity before and after RYGB in patients with and without T2D. Metabolic characteristics of obese patients with type 2 diabetes (T2D) were compared to those without the disease (Non-T2D) prior to and one- and six-months after RYGB. Fasting plasma insulin and the insulin:glucagon ratio were markedly reduced as early as one month after RYGB in both T2D and Non-T2D patients. Despite this reduction, endogenous glucose production and fasting plasma glucose levels were lower in both groups after RYGB, with the reductions being much larger in T2D. Plasma kisspeptin, an inhibitor of insulin secretion, was reduced only in T2D after surgery. Improved hepatic glucose metabolism and lower plasma kisspeptin in T2D after RYGB may link improved hepatic function with enhanced insulin responsiveness after surgery.